News and Media

Immunicom has achieved considerable momentum through major clinical trials and regulatory milestones.  It has an exceptional story to tell in immune-oncology through receiving FDA Breakthrough Designation, European approval (CE Mark) for metastatic TNBC, and raft of promising data across its global clinical trials for multiple indications including some that are unmet medical needs.

View our latest news and media

Press Releases


Featured News



Media Kit

Videos & Presentations

Immunicom Introduction

Immunicom Corporate Commercial

Immunopheresis® Treatment Overview

New Frontier in Immuno-Therapies Webinar

CEO Amir Jafri Presents at LSI Emerging Medtech Conference

JCA-AACR 2021 Abstract Presentation

Zoomtopia Healthcare Innovation Award

Recognitions & Awards


June 2022

NCI/NIH Awards $2M to Immunicom to initiate clinical trial at Baylor College of Medicine to treat refractory ER+/Her2- breast cancer

November 2021

Terumo BCT and Immunicom establish limited commercialization agreement

September 2021

Start of pre-clinical trials for the EN-06 cartridge, the second product of the Immunopheresis® therapy platform

October 2020

First patient enrolled in multi-arm clinical trial at Acibadem Healthcare Group hospitals to evaluate Immunopheresis® for non-small cell lung cancer in combination with Roche’s pharmaceutical checkpoint inhibitor, Tecentriq®

July 2020

First patient enrolled in clinical trial at Sheba Medical Center to investigate the outcomes of Immunopheresis® as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, TNBC, renal cell carcinoma and non-small cell lung cancer

May 2020

The Immunopheresis® LW-02 cartridge received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory TNBC

July 2019

Immunicom hosted the first Annual Global Immunopheresis Conference in Krakow, Poland

June 2019

First patient enrolled in multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis® as a treatment for patients with TNBC

August 2018

Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic

May 2018

The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer

December 2017

University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology

February 2016

End of pre-clinical canine trail, achieving 300 Immunopheresis® treatments. Overall, 50-60% of the canine patients treated were observed to have either a stable disease or partial response and one canine experienced a complete response with clearance of metastases.

December 2015

Completed $5.5M Series a Preferred Stock financing

May 2014

Start of pre-clinical canine trial

January 2014

Immunicom enters into a strategic partnership with Terumo BCT, an industry leading manufacturer of therapeutic apheresis equipment


Founded by Amir Jafri

Get in touch today

Let’s talk about what we can achieve together

Learn more about
our team